Stocks · News reference

Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

Sep 23, 2026, 12:03 PMBenzinga Newsdesk

Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 23, 2026, 10:56 AMBenzinga Newsdesk
ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension
Approval for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®."The FDA approval of
ANIP
SEC EDGARAug 24, 2026, 11:01 AMSEC EDGAR
8-K filing — ANI PHARMACEUTICALS INC (ANIP)
Filed: 2026-08-24 AccNo: 0001023024-26-000071 Size: 173 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
ANIP
BenzingaAug 10, 2026, 2:39 PMAvi Kapoor
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.
ANIP